CONTEMPORARY REVIEWComparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials
Introduction
Sustained ventricular tachycardias (VTs) represent the most frequent cause of sudden cardiac death. Over the last decade, after the results of pivotal clinical trials showing the efficacy of implantable cardioverter-defibrillators (ICDs) in reducing mortality attributable to sustained VT in high-risk patients, ICD use has dramatically expanded.1 Prevention of recurrent VT in patients with an ICD represents an important therapeutic target, given the demonstrated association between ICD shocks with impaired quality of life and increased mortality.2 Repetitive device intervention to terminate VT may damage the myocardium and worsen the underlying cardiac condition,3 and is associated with a significant burden of physical and psychological stress for patients. Recent evidences from primary prevention ICD populations have shown the benefit of device programming in reducing the risk of both appropriate and inappropriate device interventions and improving mortality.4 However, device programming does not prevent VT occurrence/recurrence, and many patients may continue to experience arrhythmia-related symptoms, including dizziness, palpitations, and syncope. Current approaches to prevent repeated ICD therapies include antiarrhythmic drugs (AADs) and catheter ablation (CA). Studies evaluating the efficacy of AAD or CA in preventing recurrent VT in ICD patients have provided mixed results with varying treatment effect.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 In addition, whether prevention of VT translates into a mortality benefit is unclear. We performed a systematic review and meta-analysis of randomized controlled trials in order to better evaluate and compare the benefit of AAD or CA in preventing recurrent VT in patients with an ICD.
Section snippets
Methods
We followed a standard study protocol developed by the Cochrane Collaboration19 and adapted to the present meta-analysis as previously published.20
Search results and study selection
The search permitted the retrieval of 2131 citations. After removing duplicate citations, 1648 potentials studies were considered for further screening. All of the studies selected for further scrutiny were in English language. A total of 1612 studies were excluded after assessment of the full text. An additional 10 studies were excluded because of nonrandomized design. Of the randomized trials, 3 studies were excluded because they included only patients without an ICD, and 9 studies were
Discussion
This study was specifically designed to assess and compare the efficacy of AADs and CA in reducing the risk of recurrent VT in patients with ICD and is based on the statistical pooling of 14 randomized controlled trials that included >2000 patients. The major findings of our analysis are as follows. (1) both AADs and CA significantly reduce of the risk of recurrent VT leading to appropriate ICD interventions compared to control medical therapy, with no significant difference between the 2
Conclusion
This systematic review presents a meta-analysis of data from 14 randomized controlled studies that evaluated AADs or CA for the prevention of recurrent VT in patients with ICD and shows that both AADs (amiodarone) and CA reduce the risk of recurrent VT compared to control medical therapy, without significant differences between the 2 therapeutic strategies. AADs are also associated with a reduction of inappropriate ICD therapies. The significant reduction of recurrent VT episodes does not
References (32)
- et al.
Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment
J Am Coll Cardiol
(1999) - et al.
Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator
Am J Cardiol
(1998) - et al.
Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators
J Am Coll Cardiol
(2004) - et al.
Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial
Lancet
(2010) - et al.
Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications
J Am Coll Cardiol
(1998) - et al.
EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA)
Heart Rhythm
(2009) - et al.
OMNI study investigators. Time course of appropriate implantable cardioverter-defibrillator therapy and implications for guideline-based driving restrictions
Heart Rhythm
(2015) - et al.
Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review
Heart Rhythm
(2012) - et al.
Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses
J Am Coll Cardiol
(2011) - et al.
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators
Lancet
(1997)
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators
Lancet
Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease
Heart Rhythm
2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society
J Am Coll Cardiol
Prognostic importance of defibrillator shocks in patients with heart failure
N Engl J Med
Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks
J Cardiovasc Electrophysiol
Reduction in inappropriate therapy and mortality through ICD programming
N Engl J Med
Cited by (131)
Electrical storm in patients with Automatic Implantable Defibrillator : A single Center study
2023, Annales de Cardiologie et d'AngeiologieQuelling the Storm: A Review of the Management of Electrical Storm
2023, Journal of Cardiothoracic and Vascular AnesthesiaCatheter Ablation of Ventricular Arrhythmia in Patients With an Implantable Cardioverter-Defibrillator: A Systematic Review and Meta-analysis
2023, Canadian Journal of CardiologyMechanisms of Ventricular Arrhythmias and Implications for Catheter Ablation
2022, Cardiac Electrophysiology Clinics
Funded in part by the Susan and Murray Bloom Research Fund.